U.S. FDA probes cognitive impact of new cholesterol drugs; Regeneron, Sanofi shares fall

March 7 (Reuters) - The U.S. Food and Drug Administration has called for an assessment of potential neurocognitive side effects of an experimental cholesterol drug being developed by Regeneron and Sanofi, Sanofi said in its annual report on Friday.